KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900

Drug Appears Well Positioned Vs. Approved Therapies

 
• By Alaric DeArment
  
angioedema word cube with background
KalVista announced positive Phase II data for oral HAE drug KVD900. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip